compani
takeaway follow
outlook strong go
promis big surpris guidanc call less deliv
encourag new guid come consensu
revenu ahead non-gaap ep midpoint ahead
previou revenu goal driven primarili continu top-line growth expens
manag top- bottom-lin growth expect continu beyond
approv new drug label expans mid-to-high oper
margin potenti materi follow guidanc call see
posit lilli young commerci clinic portfolio strong versu peer
updat estim accordingli reiter buy rate po
young commerci portfolio suppli half sale
lilli young product cycl limit patent loss overhang continu major
differenti lilli growth key product trulic jardianc taltz verzenio
emgal etc expect contribut half total sale net
price pressur expect higher sale almost entir volum driven
still expect trulic gener sale repres
y/i growth in-lin consensu primarili driven class
expans y/i estim potenti label inclus
cardiovascular cv risk benefit high-dos formul ad increment
util addit upsid consensu could come jardianc
emgal reyvow sale
invest thesi lilli go primarili driven stronger
expect commerci busi phase top-lin data tirzepatid diabet
mirikizumab psoriasi solanezumab alzheim provid addit
excit around stock lilli earli oncolog pipelin btk inhibitor
kra inhibitor serd breast cancer
enrol patient like come clearer focu end
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani
larg diversifi
biopharmaceut compani develop drug
treatment varieti disord includ
diabet migrain cancer rang
busi develop drug
year time
compani retain focu almost exclus
remain differenti versu peer
revenu non-gaap ep remain
bullish lilli key valu driver trulic
jardianc taltz psoriasi olumi
arthriti emgal migrain verzenio
overal view risk reward profil lilli
compel high qualiti differenti growth
modest expect ad pipelin valu
compani decemb
compani decemb
compani
price object base probability-adjust net present valu npv
analysi franchis vertic includ endocrinolog oncolog
pharmaceut product earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product depend stage develop appli
termin valu rang cardiolog pipelin base project sale
declin follow loss exclus within busi vertic
risk price object better expect launch compet
product emerg clinic data pipelin asset confirm prior
observ failur effect commerci approv product potenti
drug price system restructur us
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
compani decemb
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani decemb
